1d
MedPage Today on MSNHigh Price of GLP-1 Agents Tip Cost-Benefit Scale UnfavorablyTirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...
G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...
2don MSN
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...
21h
MedPage Today on MSNStudies Hint at Potential Negative Effects of GLP-1 Drugs in Orthopedic PatientsSAN DIEGO -- Two retrospective studies hinted at potential negative effects of GLP-1 receptor agonists for patients requiring ...
While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...
Anti-obesity drugs are only part of the larger treatment plan for most patients. Exercise and nutrition are also keys.
As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.
Increasing access to these effective evidence-based treatments would benefit our society as a whole, not just those impacted ...
With increasing demand and higher costs, ensuring appropriate patient access is more critical than ever and 2025 will likely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results